Correct way to take Erdafitinib and recommended daily dose

Erdafitinib is an oral targeted drug mainly used to treat patients with locally advanced or metastatic urothelial carcinoma carrying FGFR gene mutations or fusions. Proper administration and dosage are crucial to ensure therapeutic efficacy and reduce the risk of side effects. This article will briefly introduce the medication guidelines and dosage adjustment principles of erdafitinib.

Erdafitinib is usually taken as an oral tablet, with the recommended starting dose being 8mg once daily as a single dose. Patients should choose to take the medicine at a fixed time, and it is recommended to take it after meals to reduce gastrointestinal discomfort. When taking the medicine, swallow the tablet whole and avoid chewing or crushing to ensure effective release of the medicine. If the medication time is missed due to a missed dose, the patient should take it as soon as possible, but if it is close to the next dose time, the missed dose should be skipped and avoid taking two doses at one time.

After treatment starts, blood phosphorus levels are usually tested around the 7th day. Based on the patient's tolerance, the doctor may adjust the dose to 9 mg or 10 mg per day. Monitoring of serum phosphorus is very critical, because one of the common side effects of erdafitinib is hyperphosphatemia. If serum phosphate is too high, corresponding dose adjustment or drug discontinuation measures must be taken. In addition, regular testing of liver and kidney function and eye examinations are required to detect potential adverse reactions early.

If the patient experiences serious adverse reactions such as severe rash, vision problems, abnormal liver function, etc., the doctor will adjust the dose or temporarily discontinue the drug according to the specific situation. Elderly patients and those with impaired liver and kidney function need to be more cautious in initial dose selection and make individual adjustments to ensure safety. Patients should avoid concurrent use of drugs that may affect the metabolism of erdafitinib, such as strong CYP3A4 inhibitors or inducers.

In short, following the doctor's guidance, taking erdafitinib rationally, and combining strict safety monitoring are the keys to ensuring the therapeutic effect and medication safety. Patients should pay close attention to physical changes during the medication process, report abnormal symptoms to the doctor in a timely manner, and use medication scientifically and rationally to maximize the benefit from erdafitinib treatment.

Reference: https://go.drugbank.com/drugs/